The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Evaluation of the GenoType MTBDRplus Assay for Rifampin and Isoniazid Susceptibility Testing of Mycobacterium tuberculosis Strains and Clinical Specimens
Open accessAbstract
The new GenoType MTBDRplus assay (Hain Lifescience GmbH, Nehren, Germany) was tested with 125 clinical isolates and directly with 72 smear-positive sputum specimens for its ability to detect rifampin (RMP) and isoniazid (INH) resistance in Mycobacterium tuberculosis complex (MTBC) strains. In total, 106 RMP r /INH r , 10 RMP s /INH r , and 80 RMP s / INH s MTBC strains were comparatively analyzed with the new and the old MTBDR assays. Besides the detection of mutations within the 81-bp hot spot region of rpoB and katG codon 315, the GenoType MTBDRplus assay is designed to detect mutations in the regulatory region of inhA . The applicability of the new assay directly to specimens was shown, since 71 of 72 results for smear-positive sputa and all 125 results for clinical isolates were interpretable and no discrepancies compared with the results of real-time PCR or DNA sequencing were obtained. In comparison to conventional drug susceptibility testing, both assays were able to identify RMP resistance correctly in 74 of 75 strains (98.7%) and 30 of 31 specimens (96.8%). The misidentification of RMP resistance was obtained for two strains containing rpoB P533L mutations. Compared to the old MTBDR assay, the new GenoType MTBDRplus assay enhanced the rate of detection of INH resistance from 66 (88.0%) to 69 (92.0%) among the 75 INH-resistant strains and 36 (87.8%) to 37 (90.2%) among the 41 specimens containing INH-resistant strains. Thus, the new GenoType MTBDRplus assay represents a reliable and upgraded tool for the detection of INH and RMP resistance in strains or directly from smear-positive specimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1969) · Europe PMC (PubMed Central) · Cited by 765
Treatment of 171 Patients with Pulmonary Tuberculosis Resistant to Isoniazid and Rifampin
Goble, M., Iseman, M. D., Madsen, L. A., Waite, D., Ackerson, L., & Horsburgh, C. R. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302253280802 · Cited by 698
Hazbón, M. H., Brimacombe, M., Bobadilla del Valle, M., Cavatore, M., Guerrero, M. I., Varma-Basil, M., Billman-Jacobe, H., Lavender, C., Fyfe, J., García-García, L., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00112-06 · Cited by 374
The global situation of MDR-TB
Espinal, M. A. (2003) · Tuberculosis · doi:10.1016/s1472-9792(02)00058-6 · Cited by 329
Public Health Mycobacteriology
Kent, P. (1985) · Medical Entomology and Zoology · Cited by 328
Telenti, A., Honoré, N., Bernasconi, C., March, J., Ortega, A., Heym, B., Takiff, H. E., & Cole, S. T. (1997) · Journal of Clinical Microbiology · doi:10.1128/jcm.35.3.719-723.1997 · Cited by 320
Musser, J. M., Kapur, V., Williams, D. L., Kreiswirth, B. N., van Soolingen, D., & van Embden, J. D. A. (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/173.1.196 · Cited by 313
ethA , inhA , and katG Loci of Ethionamide-Resistant Clinical Mycobacterium tuberculosis Isolates
Morlock, G. P., Metchock, B., Sikes, D., Crawford, J. T., & Cooksey, R. C. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.12.3799-3805.2003 · Cited by 288
Heep, M., Brandstätter, B., Rieger, U., Lehn, N., Richter, E., Rüsch-Gerdes, S., & Niemann, S. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.1.107-110.2001 · Cited by 240
Self-citationPiatek, A. S., Telenti, A., Murray, M. R., El-Hajj, H., Jacobs, W. R., Kramer, F. R., & Alland, D. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.1.103-110.2000 · Cited by 218
Cited by
Helb, D., Jones, M., Story, E., Boehme, C., Wallace, E., Ho, K., Kop, J., Owens, M. R., Rodgers, R., Banada, P., et al. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01463-09 · Cited by 914
Laboratory Diagnosis of Tuberculosis in Resource-Poor Countries: Challenges and Opportunities
Parsons, L. M., Somoskövi, Á., Gutierrez, C., Lee, E., Paramasivan, C. N., Abimiku, A., Spector, S., Roscigno, G., & Nkengasong, J. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00059-10 · Cited by 540
Evaluation of the analytical performance of the Xpert MTB/RIF assay
Blakemore, R., Story, E., Helb, D., Kop, J., Banada, P., Owens, M. R., Chakravorty, S., Jones, M., & Alland, D. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.00128-10 · Cited by 485
Rapid Molecular Detection of Extrapulmonary Tuberculosis by the Automated GeneXpert MTB/RIF System
Hillemann, D., Rüsch-Gerdes, S., Boehme, C., & Richter, E. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02268-10 · Cited by 413
Self-citationBarnard, M., Albert, H., Coetzee, G., O'Brien, R., & Bosman, M. E. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200709-1436oc · Cited by 391
Metadata
- Authors
- Hillemann, D., Rüsch-Gerdes, S., & Richter, E.
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2007-08
- Volume
- 45
- Issue
- 8
- Pages
- 2635-2640
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- OpenAlex
- W2153385431
- Cited by
- 345
- References
- 22
- FWCI
- 14.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of the GenoType MTBDRplus Assay for Rifampin and Isoniazid Susceptibility Testing of Mycobacterium tuberculosis Strains and Clinical Specimens. https://app.cochat.ai/papers/10.1128/jcm.00521-07
- The paper
- Hillemann, D., Rüsch-Gerdes, S., & Richter, E. (2007). Evaluation of the GenoType MTBDRplus Assay for Rifampin and Isoniazid Susceptibility Testing of Mycobacterium tuberculosis Strains and Clinical Specimens. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.00521-07
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.